

### **International Office**

#### **Everest Biotech Ltd**

Vector Laboratories, Inc. 6737 Mowry Ave Newark, CA 94560 United States

**Customer Service:** 

customerservice@vectorlabs.com

Technical Service:

technical@vectorlabs.com

Tel: +1 (800) 227-6666

www.everestbiotech.com

Research Use Only. Not for diagnostic or therapeutic use.

# EB06448 - Goat Anti-Survivin / BIRC5 Antibody

Size: 100µg specific antibody in 200µl



## **Target Protein**

**Principal Names:** BIRC5, survivin, API4, EPR-1, baculoviral IAP repeat-containing 5 (survivin), apoptosis inhibitor 4, baculoviral IAP repeat-containing 5, baculoviral IAP

repeat-containing protein 5, survivin variant 3 alpha

Official Symbol: BIRC5

Accession Number(s): NP\_001159.2; NP\_001012271.1

Human GeneID(s): 332

Important Comments: This antibody is expected to recognize the reported isoforms 1

(NP\_001159.2) and isoform 3 (NP\_001012271.1).

## Immunogen

Peptide with sequence CVRRAIEQLAAMD, from the C Terminus of the protein sequence according to NP\_001159.2; NP\_001012271.1.

Please note the peptide is available for sale.

# **Purification and Storage**

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Aliquot and store at -20°C. Minimize freezing and thawing.

# **Applications Tested**

Peptide ELISA: antibody detection limit dilution 1:16000.

**Western blot:** Approx 18kDa band observed in Human T cell line MOLT4 lysates (calculated MW of 16.4kDa according to NP\_001159.2 and 18.6kDa according to NP\_001012271.1). Recommended concentration: 0.01-0.5µg/ml.

## **Species Reactivity**

Tested: Human

Expected from sequence similarity: Human, Cat, Dog, Pig, Cow

250kDa 150kDa 100kDa 75kDa 50kDa 37kDa 25kDa 20kDa 15kDa

EB06448 (0.01μg/ml) staining of Molt-4 lysate (35μg protein in RIPA buffer). Primary incubation was 1 hour.

Detected by chemiluminescence.